Do you know?

The FDA has granted fast track designation to Annamycin for treatment of patients with relapsed or refractory acute myeloid leukemia.

Annamycin (Moleculin Biotech) is a liposome-formulated anthracycline designed to eliminate cardiotoxicity and avoid multidrug resistance mechanisms associated with other approved anthracyclines.

The agent is being evaluated in separate phase 1 and phase 2 trials in the United States and Europe.

Studies in animal models showed the agent to be noncardiotoxic. Trials that included patients with leukemia showed the agent was associated with fewer dose-limiting toxicities than typically experienced with doxorubicin, according to Moleculin.

Explore more about hematology/ oncology at: https://hematology.cmesociety.com/

Source: https://www.healio.com/hematology-oncology/leukemia/news/online/%7B59c6cf34-2eec-4605-a347-f477d91a927d%7D/fda-grants-fast-track-designation-to-annamycin-for-relapsedrefractory-acute-myeloid-leukemia